In the world of Contract Development and Manufacturing Organizations (CDMO), building and maintaining trusted relationships is essential for success. Thermo Fisher Scientific, a leading player in the pharmaceutical services industry, understands the importance of fostering strong partnerships with their clients. Jennifer Cannon, who leads the commercial organization for Thermo Fisher’s CDMO division, shares valuable insights into the company’s approach to collaboration and customer satisfaction.
Embracing Outcome-Based Contracting for Enhanced Efficiency
Thermo Fisher is dedicated to enhancing the efficiency of drug development processes by moving towards outcome-based contracting. This approach involves committing to specific timelines that are notably faster than traditional fragmented supply chains. By providing a guarantee of performance, Thermo Fisher aims to support biotech companies in accelerating their drug development timelines, ultimately helping them bring life-saving therapies to market sooner.
Through years of experience and expertise in CDMO services, Thermo Fisher has gained the confidence to introduce outcome-based contracting. This bold step signifies a shift towards a more collaborative and results-driven model, where both parties are aligned towards achieving success in a timely manner. By offering this level of commitment, Thermo Fisher not only instills trust but also demonstrates their dedication to being a reliable partner in the drug development journey.
Navigating the Path to Commercialization with Trusted Partners
The road to commercializing a pharmaceutical product is filled with challenges and uncertainties. Having a dependable partner by your side can make all the difference in overcoming obstacles and achieving milestones effectively. Thermo Fisher understands the importance of providing continuous support to their clients throughout the development and manufacturing process.
By fostering strong relationships built on transparency and data-driven insights, Thermo Fisher ensures that their clients have full visibility into the progress of their projects. The MySupply platform, a unique offering from Thermo Fisher, allows customers to track the status of their batches in real-time, monitor key metrics such as on-time delivery and yield, and collaborate seamlessly with the Thermo Fisher team. This level of transparency and open communication is a testament to Thermo Fisher’s commitment to customer satisfaction and project success.
Insights from CPHI: A Decade of Evolution in Pharma
Jennifer Cannon reflects on her 13 years of attending the CPHI conference and highlights the evolution of the event over the years. What was once predominantly focused on small-molecule modalities has now expanded to include a diverse range of customers working on large-molecule and emerging cell and gene therapies. This shift in the landscape of pharmaceutical development underscores the need for CDMO providers to adapt to the changing needs of the industry and offer innovative solutions to their clients.
As the pharmaceutical industry continues to advance rapidly, the role of CDMOs in supporting drug development processes becomes increasingly crucial. By staying at the forefront of industry trends and leveraging their expertise, companies like Thermo Fisher can drive innovation, accelerate timelines, and ultimately contribute to the discovery of new therapies that can improve patient outcomes worldwide.
Key Takeaways:
– Outcome-based contracting offers a faster and more efficient approach to drug development timelines.
– Transparency, data-driven insights, and collaboration are crucial for successful partnerships in CDMO services.
– The evolution of industry events like CPHI reflects the changing landscape of pharmaceutical development and the growing importance of advanced therapies.
Tags: clinical trials, formulation, process development, biotech
Read more on pharmtech.com